Lipotoxicity and immunometabolism in ischemic acute kidney injury: current perspectives and future directions

Afolarin A Otunla; Kumaran Shanmugarajah; Alun H Davies; Joseph Shalhoub

doi:10.3389/fphar.2024.1355674

Lipotoxicity and immunometabolism in ischemic acute kidney injury: current perspectives and future directions

Front Pharmacol. 2024 Feb 23:15:1355674. doi: 10.3389/fphar.2024.1355674. eCollection 2024.

Authors

Afolarin A Otunla¹, Kumaran Shanmugarajah², Alun H Davies³, Joseph Shalhoub³

Affiliations

¹ Department of Surgical Biotechnology, University College London, London, United Kingdom.
² Cleveland Clinic, Cleveland Clinic Transplant Centre, Cleveland, OH, United States.
³ UK and Imperial Vascular Unit, Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, Imperial College Healthcare NHS Trust, London, United Kingdom.

Abstract

Dysregulated lipid metabolism is implicated in the pathophysiology of a range of kidney diseases. The specific mechanisms through which lipotoxicity contributes to acute kidney injury (AKI) remain poorly understood. Herein we review the cardinal features of lipotoxic injury in ischemic kidney injury; lipid accumulation and mitochondrial lipotoxicity. We then explore a new mechanism of lipotoxicity, what we define as "immunometabolic" lipotoxicity, and discuss the potential therapeutic implications of targeting this lipotoxicity using lipid lowering medications.

Keywords: acute kidney injury; immunometabolism; ischemia; lipotoxicity; mitcohondria.

Publication types

Review

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.